Triple-Negative Breast Cancer Vaccine Trial: Cleveland Clinic’s Groundbreaking Research

Cleveland Clinic researchers have embarked on an innovative study aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, this groundbreaking research represents a significant step forward in the quest for effective breast cancer prevention strategies.

Targeting Triple-Negative Breast Cancer

Triple-negative breast cancer poses a formidable challenge in the realm of oncology, lacking effective treatment options compared to other breast cancer subtypes. Recognizing the urgent need for improved interventions, Cleveland Clinic researchers are pioneering a preventive vaccine designed to target this aggressive form of breast cancer.

Novel Approach to Prevention

The vaccine, based on pre-clinical research led by the late Dr. Vincent Tuohy, targets a lactation protein called α-lactalbumin, which is prevalent in the majority of triple-negative breast cancers. The vaccine aims to activate the immune system to recognize and attack cancer cells, potentially thwarting tumor growth and progression.

Participate in Clinical Trial for Triple-Negative Breast Cancer Prevention

If you or anyone you know may want to participate in this revolutionary new breast cancer trial, you can find more details below. This trial investigates the alpha-lactalbumin vaccine, a promising immunotherapy designed for individuals previously treated for stage II or III triple-negative breast cancer.

Eligibility Criteria:

  • Completion of treatment for stage II or III triple-negative breast cancer within the past three years.
  • Absence of ER, PR, and HER2 receptors, or low HER2 expression in the cancer profile.

Trial Information:

  • Location: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH
  • Visits: 3 visits within one month
  • Phase: Not Applicable
  • NCT ID: NCT04674306

Objective: To evaluate the vaccine’s safety, optimal dosage, therapeutic effects, and anti-cancer properties, offering a potential breakthrough in preventive care.

Clinical Trial Advancements

Building on earlier research successes, Cleveland Clinic has launched a phase 1b clinical trial focusing on cancer-free individuals at high risk of developing breast cancer. Participants, who typically carry genetic mutations predisposing them to triple-negative breast cancer, will undergo prophylactic mastectomy and receive three vaccinations over a two-week period. The trial aims to evaluate safety and monitor immune response, with results anticipated by the end of 2023.

Empowering Breast Health Awareness with LLL

In light of this groundbreaking research on preventive breast cancer vaccination, Learn Look Locate (LLL) remains committed to disseminating cutting-edge information and empowering individuals with knowledge about breast health and treatment options.